Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial
Bevacizumab is a humanized antihuman VEGF-A monoclonal antibody. This study aims to evaluate the efficacy and safety of intraperitoneal administration of cisplatin plus bevacizumab (Avastin) in the management of malignant ascites in ovarian epithelial cancer. Fifty-eight ovarian epithelial cancer pa...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2015-02, Vol.32 (2), p.292-292, Article 37 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 292 |
|---|---|
| container_issue | 2 |
| container_start_page | 292 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 32 |
| creator | Zhao, Hui Li, Xiaosong Chen, Dianjun Cai, Jianhua Fu, Yan Kang, Huanrong Gao, Jie Gao, Ke Du, Nan |
| description | Bevacizumab is a humanized antihuman VEGF-A monoclonal antibody. This study aims to evaluate the efficacy and safety of intraperitoneal administration of cisplatin plus bevacizumab (Avastin) in the management of malignant ascites in ovarian epithelial cancer. Fifty-eight ovarian epithelial cancer patients with malignant ascites were randomly assigned to receive either intraperitoneal administration of cisplatin only (control group,
n
= 27, cisplatin: 40 mg/m
2
every 2 weeks, for 6 weeks) or cisplatin plus bevacizumab (study group,
n
= 31, cisplatin: 40 mg/m
2
, bevacizumab: 300 mg, every 2 weeks for 6 weeks). All patients regularly received TC regimen (paclitaxel 135 mg/m
2
d1 + carboplatin AUC 5 d1) every 3 weeks. The outcome, quality of life (QoL) and adverse effect of the treatment were analyzed, and VEGF and CA-125 level in ascites were detected by ELISA. After treatment with cisplatin plus bevacizumab, VEGF level in ascites was significantly decreased compared to baseline (
P
|
| doi_str_mv | 10.1007/s12032-014-0292-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1652396384</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1652396384</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-3eb75ff734d52a65d5b4a34971b2ca8e38c08edf1f95f7363f7a1ceb502df9f53</originalsourceid><addsrcrecordid>eNp1kU2L1jAQx4so7rr6AbxIwIuXal6atPUmiy-FBS8K3so0nTybJU1rki7oJ_JjOo_PKiJ4SjL5_WYG_lX1VPCXgvP2VRaSK1lz0dRc9rIW96pzoXVfCyW-3Ke70m3NteFn1aOcbziXQsv-YXUmqdZzbs6rH0MsCTZMvqwRITCYFx99pmLxa2SrY9bnLdArsi3smU14C9Z_3xeYmFsTK9fIFohwwAVjOQoLBH-IQA_I1hfMjNz1FpKHyHDzZARPoyxEi-k1S5j3UPJRBbZdQ0Y2DAOzgRaxxBUSw-PqgYOQ8cndeVF9fvf20-WH-urj--HyzVVtG9OVWuHUauda1cxagtGznhpQTd-KSVroUHWWdzg74XpNlFGuBWFx0lzOrndaXVQvTn23tH7dMZdx8dliCBBx3fMojJaqN6prCH3-D3qz7inSdr8oI1sjOqLEibJpzTmhG7fkF0jfRsHHY4zjKcaRYhyPMY6CnGd3nfdpwfmP8Ts3AuQJyPQVD5j-Gv3frj8Bwfareg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1652627618</pqid></control><display><type>article</type><title>Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Zhao, Hui ; Li, Xiaosong ; Chen, Dianjun ; Cai, Jianhua ; Fu, Yan ; Kang, Huanrong ; Gao, Jie ; Gao, Ke ; Du, Nan</creator><creatorcontrib>Zhao, Hui ; Li, Xiaosong ; Chen, Dianjun ; Cai, Jianhua ; Fu, Yan ; Kang, Huanrong ; Gao, Jie ; Gao, Ke ; Du, Nan</creatorcontrib><description>Bevacizumab is a humanized antihuman VEGF-A monoclonal antibody. This study aims to evaluate the efficacy and safety of intraperitoneal administration of cisplatin plus bevacizumab (Avastin) in the management of malignant ascites in ovarian epithelial cancer. Fifty-eight ovarian epithelial cancer patients with malignant ascites were randomly assigned to receive either intraperitoneal administration of cisplatin only (control group,
n
= 27, cisplatin: 40 mg/m
2
every 2 weeks, for 6 weeks) or cisplatin plus bevacizumab (study group,
n
= 31, cisplatin: 40 mg/m
2
, bevacizumab: 300 mg, every 2 weeks for 6 weeks). All patients regularly received TC regimen (paclitaxel 135 mg/m
2
d1 + carboplatin AUC 5 d1) every 3 weeks. The outcome, quality of life (QoL) and adverse effect of the treatment were analyzed, and VEGF and CA-125 level in ascites were detected by ELISA. After treatment with cisplatin plus bevacizumab, VEGF level in ascites was significantly decreased compared to baseline (
P
< 0.05). Meanwhile, ascites VEGF level of study group was significantly lower than that of control group (
P
< 0.05). The overall response rate (ORR) of study group was significantly higher than that of control group (ORR 90.32 vs. 59.26 %,
P
< 0.05). QoL improvement rate of study group was also significantly higher than that of control group (93.55 vs. 48.15 %,
P
< 0.05). All patients were well tolerated, and no serious adverse effect occurred. Intraperitoneal administration of cisplatin plus bevacizumab is effective and safe for the management of malignant ascites in ovarian epithelial cancer.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-014-0292-1</identifier><identifier>PMID: 25609006</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Aged ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Ascites - drug therapy ; Ascites - etiology ; Bevacizumab ; CA-125 Antigen - analysis ; Carcinoma, Ovarian Epithelial ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Enzyme-Linked Immunosorbent Assay ; Female ; Hematology ; Humans ; Injections, Intraperitoneal ; Internal Medicine ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasms, Glandular and Epithelial - complications ; Neoplasms, Glandular and Epithelial - drug therapy ; Oncology ; Original Paper ; Ovarian Neoplasms - complications ; Ovarian Neoplasms - drug therapy ; Pathology ; Quality of Life ; Vascular Endothelial Growth Factor A - analysis</subject><ispartof>Medical oncology (Northwood, London, England), 2015-02, Vol.32 (2), p.292-292, Article 37</ispartof><rights>Springer Science+Business Media New York 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-3eb75ff734d52a65d5b4a34971b2ca8e38c08edf1f95f7363f7a1ceb502df9f53</citedby><cites>FETCH-LOGICAL-c468t-3eb75ff734d52a65d5b4a34971b2ca8e38c08edf1f95f7363f7a1ceb502df9f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-014-0292-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-014-0292-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25609006$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Hui</creatorcontrib><creatorcontrib>Li, Xiaosong</creatorcontrib><creatorcontrib>Chen, Dianjun</creatorcontrib><creatorcontrib>Cai, Jianhua</creatorcontrib><creatorcontrib>Fu, Yan</creatorcontrib><creatorcontrib>Kang, Huanrong</creatorcontrib><creatorcontrib>Gao, Jie</creatorcontrib><creatorcontrib>Gao, Ke</creatorcontrib><creatorcontrib>Du, Nan</creatorcontrib><title>Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>Bevacizumab is a humanized antihuman VEGF-A monoclonal antibody. This study aims to evaluate the efficacy and safety of intraperitoneal administration of cisplatin plus bevacizumab (Avastin) in the management of malignant ascites in ovarian epithelial cancer. Fifty-eight ovarian epithelial cancer patients with malignant ascites were randomly assigned to receive either intraperitoneal administration of cisplatin only (control group,
n
= 27, cisplatin: 40 mg/m
2
every 2 weeks, for 6 weeks) or cisplatin plus bevacizumab (study group,
n
= 31, cisplatin: 40 mg/m
2
, bevacizumab: 300 mg, every 2 weeks for 6 weeks). All patients regularly received TC regimen (paclitaxel 135 mg/m
2
d1 + carboplatin AUC 5 d1) every 3 weeks. The outcome, quality of life (QoL) and adverse effect of the treatment were analyzed, and VEGF and CA-125 level in ascites were detected by ELISA. After treatment with cisplatin plus bevacizumab, VEGF level in ascites was significantly decreased compared to baseline (
P
< 0.05). Meanwhile, ascites VEGF level of study group was significantly lower than that of control group (
P
< 0.05). The overall response rate (ORR) of study group was significantly higher than that of control group (ORR 90.32 vs. 59.26 %,
P
< 0.05). QoL improvement rate of study group was also significantly higher than that of control group (93.55 vs. 48.15 %,
P
< 0.05). All patients were well tolerated, and no serious adverse effect occurred. Intraperitoneal administration of cisplatin plus bevacizumab is effective and safe for the management of malignant ascites in ovarian epithelial cancer.</description><subject>Aged</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Ascites - drug therapy</subject><subject>Ascites - etiology</subject><subject>Bevacizumab</subject><subject>CA-125 Antigen - analysis</subject><subject>Carcinoma, Ovarian Epithelial</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Injections, Intraperitoneal</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasms, Glandular and Epithelial - complications</subject><subject>Neoplasms, Glandular and Epithelial - drug therapy</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Ovarian Neoplasms - complications</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Pathology</subject><subject>Quality of Life</subject><subject>Vascular Endothelial Growth Factor A - analysis</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU2L1jAQx4so7rr6AbxIwIuXal6atPUmiy-FBS8K3so0nTybJU1rki7oJ_JjOo_PKiJ4SjL5_WYG_lX1VPCXgvP2VRaSK1lz0dRc9rIW96pzoXVfCyW-3Ke70m3NteFn1aOcbziXQsv-YXUmqdZzbs6rH0MsCTZMvqwRITCYFx99pmLxa2SrY9bnLdArsi3smU14C9Z_3xeYmFsTK9fIFohwwAVjOQoLBH-IQA_I1hfMjNz1FpKHyHDzZARPoyxEi-k1S5j3UPJRBbZdQ0Y2DAOzgRaxxBUSw-PqgYOQ8cndeVF9fvf20-WH-urj--HyzVVtG9OVWuHUauda1cxagtGznhpQTd-KSVroUHWWdzg74XpNlFGuBWFx0lzOrndaXVQvTn23tH7dMZdx8dliCBBx3fMojJaqN6prCH3-D3qz7inSdr8oI1sjOqLEibJpzTmhG7fkF0jfRsHHY4zjKcaRYhyPMY6CnGd3nfdpwfmP8Ts3AuQJyPQVD5j-Gv3frj8Bwfareg</recordid><startdate>20150201</startdate><enddate>20150201</enddate><creator>Zhao, Hui</creator><creator>Li, Xiaosong</creator><creator>Chen, Dianjun</creator><creator>Cai, Jianhua</creator><creator>Fu, Yan</creator><creator>Kang, Huanrong</creator><creator>Gao, Jie</creator><creator>Gao, Ke</creator><creator>Du, Nan</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20150201</creationdate><title>Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial</title><author>Zhao, Hui ; Li, Xiaosong ; Chen, Dianjun ; Cai, Jianhua ; Fu, Yan ; Kang, Huanrong ; Gao, Jie ; Gao, Ke ; Du, Nan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-3eb75ff734d52a65d5b4a34971b2ca8e38c08edf1f95f7363f7a1ceb502df9f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Ascites - drug therapy</topic><topic>Ascites - etiology</topic><topic>Bevacizumab</topic><topic>CA-125 Antigen - analysis</topic><topic>Carcinoma, Ovarian Epithelial</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Injections, Intraperitoneal</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasms, Glandular and Epithelial - complications</topic><topic>Neoplasms, Glandular and Epithelial - drug therapy</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Ovarian Neoplasms - complications</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Pathology</topic><topic>Quality of Life</topic><topic>Vascular Endothelial Growth Factor A - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Hui</creatorcontrib><creatorcontrib>Li, Xiaosong</creatorcontrib><creatorcontrib>Chen, Dianjun</creatorcontrib><creatorcontrib>Cai, Jianhua</creatorcontrib><creatorcontrib>Fu, Yan</creatorcontrib><creatorcontrib>Kang, Huanrong</creatorcontrib><creatorcontrib>Gao, Jie</creatorcontrib><creatorcontrib>Gao, Ke</creatorcontrib><creatorcontrib>Du, Nan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Hui</au><au>Li, Xiaosong</au><au>Chen, Dianjun</au><au>Cai, Jianhua</au><au>Fu, Yan</au><au>Kang, Huanrong</au><au>Gao, Jie</au><au>Gao, Ke</au><au>Du, Nan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2015-02-01</date><risdate>2015</risdate><volume>32</volume><issue>2</issue><spage>292</spage><epage>292</epage><pages>292-292</pages><artnum>37</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>Bevacizumab is a humanized antihuman VEGF-A monoclonal antibody. This study aims to evaluate the efficacy and safety of intraperitoneal administration of cisplatin plus bevacizumab (Avastin) in the management of malignant ascites in ovarian epithelial cancer. Fifty-eight ovarian epithelial cancer patients with malignant ascites were randomly assigned to receive either intraperitoneal administration of cisplatin only (control group,
n
= 27, cisplatin: 40 mg/m
2
every 2 weeks, for 6 weeks) or cisplatin plus bevacizumab (study group,
n
= 31, cisplatin: 40 mg/m
2
, bevacizumab: 300 mg, every 2 weeks for 6 weeks). All patients regularly received TC regimen (paclitaxel 135 mg/m
2
d1 + carboplatin AUC 5 d1) every 3 weeks. The outcome, quality of life (QoL) and adverse effect of the treatment were analyzed, and VEGF and CA-125 level in ascites were detected by ELISA. After treatment with cisplatin plus bevacizumab, VEGF level in ascites was significantly decreased compared to baseline (
P
< 0.05). Meanwhile, ascites VEGF level of study group was significantly lower than that of control group (
P
< 0.05). The overall response rate (ORR) of study group was significantly higher than that of control group (ORR 90.32 vs. 59.26 %,
P
< 0.05). QoL improvement rate of study group was also significantly higher than that of control group (93.55 vs. 48.15 %,
P
< 0.05). All patients were well tolerated, and no serious adverse effect occurred. Intraperitoneal administration of cisplatin plus bevacizumab is effective and safe for the management of malignant ascites in ovarian epithelial cancer.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>25609006</pmid><doi>10.1007/s12032-014-0292-1</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2015-02, Vol.32 (2), p.292-292, Article 37 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1652396384 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Ascites - drug therapy Ascites - etiology Bevacizumab CA-125 Antigen - analysis Carcinoma, Ovarian Epithelial Cisplatin - administration & dosage Cisplatin - adverse effects Enzyme-Linked Immunosorbent Assay Female Hematology Humans Injections, Intraperitoneal Internal Medicine Medicine Medicine & Public Health Middle Aged Neoplasms, Glandular and Epithelial - complications Neoplasms, Glandular and Epithelial - drug therapy Oncology Original Paper Ovarian Neoplasms - complications Ovarian Neoplasms - drug therapy Pathology Quality of Life Vascular Endothelial Growth Factor A - analysis |
| title | Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T22%3A11%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intraperitoneal%20administration%20of%20cisplatin%20plus%20bevacizumab%20for%20the%20management%20of%20malignant%20ascites%20in%20ovarian%20epithelial%20cancer:%20results%20of%20a%20phase%20III%20clinical%20trial&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Zhao,%20Hui&rft.date=2015-02-01&rft.volume=32&rft.issue=2&rft.spage=292&rft.epage=292&rft.pages=292-292&rft.artnum=37&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-014-0292-1&rft_dat=%3Cproquest_cross%3E1652396384%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1652627618&rft_id=info:pmid/25609006&rfr_iscdi=true |